India markets open in 38 minutes

Sysmex Corporation (SSMXF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
115.750.00 (0.00%)
At close: 2:26PM EDT

Sysmex Corporation

1-5-1, Wakinohama-Kaigandori
Kobe 651-0073
81 78 265 0500

IndustryDiagnostics & Research
Full-time employees8,445

Key executives

NameTitlePayExercisedYear born
Mr. Hisashi IetsuguChairman of the Managing Board & CEO1.2MN/A1949
Mr. Kaoru AsanoCTO, Sr. MD, Sr. Exec. Officer, Sr. MD & Member of the Managing BoardN/AN/A1958
Tomoo AramakiExec. VP of Corp. Bus. Admin.N/AN/AN/A
Mr. Iwane MatsuiMD, Sr. Exec. Officer & Member of Managing BoardN/AN/A1961
Mr. Kenji TachibanaSr. MD, Sr. Exec. Officer & Member of the Managing BoardN/AN/A1957
Mr. Hiroshi KandaMD, Sr. Exec. Officer & Member of the Managing BoardN/AN/A1957
Mr. Mamoru KubotaSr. Exec. Officer of LS Bus. UnitN/AN/AN/A
Mr. Kensuke LizukaSr. Exec. OfficerN/AN/AN/A
Mr. Tomokazu YoshidaSr. Exec. Officer, MD & Member of the Managing BoardN/AN/AN/A
Mr. Takashi OnoSr. Exec. OfficerN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. It also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, the company offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; cancer genome profiling systems; and cytogenic testing and lab assay services. It is also involved in the development and sale of software for diagnostic information systems; provision of facility management, office, and welfare services; development, manufacture, and sale of nucleic acid analogs; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. Sysmex Corporation has a strategic alliance with QIAGEN N.V. for the development and commercialization of cancer companion diagnostics using Plasma-Safe-SeqS technology. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.

Corporate governance

Sysmex Corporation’s ISS governance QualityScore as of 1 July 2021 is 3. The pillar scores are Audit: 1; Board: 6; Shareholder rights: 3; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.